Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for SYRE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 88.06M
March 31, 2026 78.84M
December 31, 2025 78.19M
September 30, 2025 60.83M
June 30, 2025 60.74M
March 31, 2025 60.28M
December 31, 2024 60.26M
September 30, 2024 51.40M
June 30, 2024 50.78M
March 31, 2024 36.63M
December 31, 2023 36.06M
September 30, 2023 4.049M
June 30, 2023 3.240M
March 31, 2023 2.616M
December 31, 2022 2.614M
September 30, 2022 2.460M
June 30, 2022 2.447M
March 31, 2022 1.977M
December 31, 2021 1.974M
September 30, 2021 1.972M
June 30, 2021 1.961M
March 31, 2021 1.961M
December 31, 2020 1.918M
September 30, 2020 1.788M
Date Value
June 30, 2020 1.784M
March 31, 2020 1.166M
December 31, 2019 1.163M
September 30, 2019 1.157M
June 30, 2019 1.154M
March 31, 2019 1.154M
December 31, 2018 0.9656M
September 30, 2018 0.8839M
June 30, 2018 0.8763M
March 31, 2018 0.6724M
December 31, 2017 0.6668M
September 30, 2017 0.6589M
June 30, 2017 0.6581M
March 31, 2017 0.5381M
December 31, 2016 0.5372M
September 30, 2016 0.5372M
June 30, 2016 0.5365M
March 31, 2016 0.5365M
December 31, 2015 0.5472M
September 30, 2015 0.5472M
June 30, 2015 0.5472M
March 31, 2015 0.5472M
December 31, 2014 0.5472M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 1.767B
Incyte Corp. 200.98M
SELLAS Life Sciences Group, Inc. 201.92M
BridgeBio Pharma, Inc. 195.28M
Relay Therapeutics, Inc. 218.53M